Featured Research

from universities, journals, and other organizations

'Live vaccine' for gonorrhea prevents reinfection

Date:
September 18, 2013
Source:
University at Buffalo
Summary:
A new gonorrhea treatment, based on an anti-cancer therapy, has successfully eliminated gonococcal infection from female mice and prevented reinfection, according to research published today.

A new gonorrhea treatment, based on an anti-cancer therapy developed by a Buffalo startup company, has successfully eliminated gonococcal infection from female mice and prevented reinfection, according to research published today by University at Buffalo scientists in the Journal of Infectious Diseases.

Related Articles


Through TherapyX Inc., an early stage biotech company in Buffalo, the UB researchers have a $300,000 Small Business Innovation Research grant to develop the technology to treat and prevent gonorrhea infection. UB's Office for Science, Technology Transfer and Economic Outreach has filed for patent protection.

More than 100 million new gonococcal infections occur each year around the globe, according to the World Health Organization, which warns of a pending gonorrhea crisis due to soaring drug resistance rates. The infection can be asymptomatic but it also can cause extremely painful urination in men and pelvic inflammatory disease, which can lead to infertility and ectopic pregnancy, in women. It may also make individuals more susceptible to infection with HIV/AIDS.

"We developed the concept that gonococcal infection seems to inhibit specific adaptive immune responses, which is, in part, why people can become infected with it multiple times," explains Michael W. Russell, PhD, professor of microbiology and immunology in the UB School of Medicine and Biomedical Sciences and senior author on the paper. "It turns out that gonococcal infection very cleverly controls the immune system, inducing responses the bacterium can fight and suppressing the responses that it cannot fight."

In considering how to modify the immune response to gonococcal infection, Russell became intrigued with an anti-cancer therapy being developed by a UB medical school colleague.

Nejat K. Egilmez, PhD, professor of microbiology and immunology at UB, and a co-author on the current paper, developed NanoCap, a sustained-release nanoparticle treatment that uses Interleukin-12, a cytokine or protein that helps stimulate an immune response against tumors that normally suppress immunity. Egilmez co-founded TherapyX Inc. to commercialize this and other drug formulations.

"We had the idea that maybe these IL-12 microspheres that they were developing against tumors could be used to generate an immune response against gonococcal infection as well," says Russell. "This research proves that they can."

The current study describes how the IL-12 microspheres, administered intravaginally in mice, resulted in the development of a specific adaptive immune response -- development of antibodies specific to N. gonorrhoeae -- and clearance of the infection within days. One month later, attempts to reinfect these mice with the bacterium failed, demonstrating that the animals had retained the ability to fight reinfection.

"With this treatment, we have reversed the immunosuppression that gonococcal infection normally causes and allowed an effective immune response to develop," says Russell. "It could be argued that when the IL-12 microspheres are administered this way, they serve as an adjuvant that, in effect, converts the gonococcal infection into a live vaccine, thus essentially vaccinating the very population that is at risk for repeat infections."

And because it may circumvent the growing resistance of this bacterium and others to antibiotics, this treatment method also may open up new approaches for the development of non-resistant treatments for other infectious diseases, Russell says.

"Here, we are delivering cytokines locally right to the site of infection," he says. "If we can use this method to teach the immune system to generate the right kind of response to other recalcitrant infections, then we could have a new approach to treat a range of infectious diseases without stimulating drug resistance."

The immunity developed in the mice lasted for one month. Russell plans to see if the immunity can last longer in mice and then ultimately, to test it in humans.


Story Source:

The above story is based on materials provided by University at Buffalo. Note: Materials may be edited for content and length.


Journal Reference:

  1. Yingru Liu, Nejat K. Egilmez, and Michael W. Russell. Enhancement of Adaptive Immunity to Neisseria gonorrhoeae by Local Intravaginal Administration of Microencapsulated Interleukin 12. Journal of Infectious Diseases, September 2013 DOI: 10.1093/infdis/jit354

Cite This Page:

University at Buffalo. "'Live vaccine' for gonorrhea prevents reinfection." ScienceDaily. ScienceDaily, 18 September 2013. <www.sciencedaily.com/releases/2013/09/130918101956.htm>.
University at Buffalo. (2013, September 18). 'Live vaccine' for gonorrhea prevents reinfection. ScienceDaily. Retrieved November 25, 2014 from www.sciencedaily.com/releases/2013/09/130918101956.htm
University at Buffalo. "'Live vaccine' for gonorrhea prevents reinfection." ScienceDaily. www.sciencedaily.com/releases/2013/09/130918101956.htm (accessed November 25, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Tuesday, November 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

From Popcorn To Vending Snacks: FDA Ups Calorie Count Rules

From Popcorn To Vending Snacks: FDA Ups Calorie Count Rules

Newsy (Nov. 25, 2014) — The US FDA is announcing new calorie rules on Tuesday that will require everywhere from theaters to vending machines to include calorie counts. Video provided by Newsy
Powered by NewsLook.com
Madagascar Working to Contain Plague Outbreak

Madagascar Working to Contain Plague Outbreak

AFP (Nov. 24, 2014) — Madagascar said Monday it is trying to contain an outbreak of plague -- similar to the Black Death that swept Medieval Europe -- that has killed 40 people and is spreading to the capital Antananarivo. Duration: 00:42 Video provided by AFP
Powered by NewsLook.com
Are Female Bosses More Likely To Be Depressed?

Are Female Bosses More Likely To Be Depressed?

Newsy (Nov. 24, 2014) — A new study links greater authority with increased depressive symptoms among women in the workplace. Video provided by Newsy
Powered by NewsLook.com
Winter Can Cause Depression — Here's How To Combat It

Winter Can Cause Depression — Here's How To Combat It

Newsy (Nov. 23, 2014) — Millions of American suffer from seasonal depression every year. It can lead to adverse health effects, but there are ways to ease symptoms. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins